Prices delayed by at least 15 minutes | Print


Royalty Pharma plc (RPRX)

Ordinary Shares
Sell: $30.37|Buy: $30.39|Change: 0.07 (-0.23%)

Open 

$30.5


Previous close 

$30.45


Trade high 

$30.8


Volume 

1,668,560


Year high 

$37.42


Year low 

$25.92


Dividend yield 

2.66%


Market capitalisation 

$13.57 bn


P/E ratio 

12.04


ISIN 

GB00BMVP7Y09


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date17/11/202316/02/2024
Ex-dividend date16/11/202315/02/2024
Payment date15/12/202315/03/2024
Amount$0.2$0.21

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Royalty Pharma plc+ 0.73
More...

Company profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.